Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetomenaphthone SCHEMBL29411342 | 0.83 | HTT (1.00) | MAPTHTTKDM4EGAAHSD17B10 | |
| Acetomenaphthone SCHEMBL209382 | 0.83 | HTT (1.00) | MAPTHTTKDM4EGAAHSD17B10 | |
| SCHEMBL30166016 | 0.82 | MAPT (0.69) | MAPTHTTKDM4EGAAHSD17B10 | |
| SCHEMBL17696404 | 0.82 | MAPT (0.69) | MAPTHTTKDM4EGAAHSD17B10 | |
| SCHEMBL3989240 | 0.82 | MAPT (0.69) | MAPTHTTKDM4EGAAHSD17B10 | |
| SCHEMBL20398637 | 0.80 | HTT (0.67) | MAPTHTTKDM4EGAAHSD17B10 | |
| SCHEMBL30434021 | 0.80 | HTT (0.67) | MAPTHTTKDM4EGAAHSD17B10 | |
| SCHEMBL9628320 | 0.80 | MAPT (0.67) | MAPTHTTKDM4EGAAHSD17B10 | |
| SCHEMBL6907648 | 0.79 | KDM4E (0.63) | MAPTHTTKDM4EGAAHSD17B10 | |
| SCHEMBL29368738 | 0.79 | KDM4E (0.63) | MAPTHTTKDM4EGAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778114-B | Efficient and environment-friendly method for synthesizing vitamin K1 | 杭州浙中医药科技有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-112778114-A | Efficient and environment-friendly method for synthesizing vitamin K1 | 杭州浙中医药科技有限公司 | 2021-05-11 | — | — | CN | claimed |
| CN-111380966-A | Method for determining related substances of vitamin K1 bulk drug | 南京艾德凯腾生物医药有限责任公司 | 2020-07-07 | — | — | CN | claimed |
| JP-56104805-A | — | — | None | — | — | JP | disclosed |
| US-20260083773-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | EPIZON PHARMA INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12514871-B2 | Pegylated menaquinol compositions and methods of treatment | Epizon Pharma, Inc. (US) | 2026-01-06 | — | — | US | disclosed |
| CN-112778114-B | Efficient and environment-friendly method for synthesizing vitamin K1 | 杭州浙中医药科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-112778114-B | Efficient and environment-friendly method for synthesizing vitamin K1 | 杭州浙中医药科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119630636-A | Pegylated alpha naphthol compositions and methods of treatment | 埃皮松制药公司 | 2025-03-14 | — | — | CN | disclosed |
| US-12103914-B2 | Compositions of biologically active menaquinol derivatives and methods of treatment | Epizon Pharma, Inc. (US) | 2024-10-01 | — | — | US | disclosed |
| WO-2023235259-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | Epizon Pharma, Inc. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20070060761-A1 | Method for producing quinone compound | EISAI CO., LTD. | 2007-03-15 | — | — | US | disclosed |
| US-20070060761-A1 | Method for producing quinone compound | EISAI CO., LTD. | 2007-03-15 | — | — | US | disclosed |
| CN-1816536-A | Cannabinoid receptor modulators | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-08-09 | — | — | CN | disclosed |
| EP-1637527-A1 | CANNABINOID RECEPTOR MODULATOR | Takeda Pharmaceutical Company Limited (JP) | 2006-03-22 | — | — | EP | disclosed |
| EP-0592962-B1 | Purification method of crude product | EISAI KAGAKU KK (JP) | 1997-07-16 | — | — | EP | disclosed |
| US-5547580-A | CHROMATOGRAPHY ON A SILICA GEL SOLID SUPPORT USING METHANOL, HEXANE MIXTURE | EISAI CHEMICAL CO., LTD. (JP) | 1996-08-20 | — | — | US | disclosed |
| EP-0592962-A1 | Purification method of crude product | EISAI CHEMICAL CO., LTD. (JP) | 1994-04-20 | — | — | EP | disclosed |
| JP-S56104805-A | NOVEL PROCESS FOR NEUTRALIZING TOXICITY OF HERBICIDE AGAINST FISH | ASAHI CHEM IND CO LTD | 1981-08-20 | — | — | JP | disclosed |
| US-3957836-A | QUINONE DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12103914-B2 | Compositions of biologically active menaquinol derivatives and methods of treatment | GLS, COQ8A, GLS2 | MAPT 3057/4885HTT 3046/4885KDM4E 4107/4885 |
| US-20070060761-A1 | Method for producing quinone compound | SDHA, SQOR, SDHB | MAPT 1598/4885HTT 2229/4885KDM4E 1682/4885 |
| US-20260083773-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | SGMS1, SGMS2, MEN1 | MAPT 4296/4885HTT 3516/4885KDM4E 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.